Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1600-0781.2011.00590.x | DOI Listing |
Publication Analysis
Top Keywords
photodistributed eruption
4
eruption rhabdomyolisis
4
rhabdomyolisis leflunomide
4
photodistributed
1
rhabdomyolisis
1
leflunomide
1
Similar Publications
Clinical Profile of Patients with Lichenoid Drug Eruption: A Observational Study.
Indian J Dermatol
April 2024
Department of Dermatology, Venereology and Leprosy, Jalpaiguri Govt. Medical College and Hospital, West Bengal, India.
Article Synopsis
- Lichenoid drug eruption (LDE) is a rare skin reaction to various medications, primarily affecting older adults, with a mean age of around 51.5 years in the study group.
- The most commonly implicated drugs are anti-hypertensives (40%) and antitubercular medications (33.4%), with skin reactions developing between 15 days to 6 months after starting the drug.
- Quick identification and stopping the suspected medication are crucial for reducing the severity of the condition, as one-third of the reactions were classified as "definite" using the Naranjo scale for adverse drug reactions.
Photodistributed Lichenoid Eruption with Alopecia: A Unique Presentation of Graham-Little-Piccardi-Lasseur Syndrome.
Int J Trichology
April 2024
Department of Dermatology, Kansas City University, Kansas, Florida, USA.
Article Synopsis
- Graham-Little-Piccardi-Lasseur syndrome (GLPLS) involves widespread hair loss and a specific skin rash on the scalp and other areas of the body, and is linked to lichen planopilaris.
- The condition typically begins with thick skin bumps and leads to hair loss, and while other forms of lichen planus can show reactions to sunlight, GLPLS had not been previously documented with such an eruption.
- This report introduces the first case of GLPLS with a sun-related rash, discussing its underlying causes and treatment options.
A photo-distributed rash and eczematous eruptions in two siblings-A diagnostic conundrum.
Australas J Dermatol
June 2024
Department of Dermatology, Venereology and Leprology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Immune checkpoint inhibitor-induced subacute cutaneous lupus erythematosus: a case report and review of the literature.
Front Med (Lausanne)
February 2024
Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States.
Article Synopsis
- Immune checkpoint inhibitors (ICIs) can lead to autoimmune side effects called immune related adverse events (irAEs), with cutaneous irAEs affecting about 50% of patients.
- ICI-induced subacute cutaneous lupus erythematosus (SCLE) has been increasingly reported and can cause prolonged skin reactions even after stopping treatment.
- This case study describes a 75-year-old man with gastro-esophageal adenocarcinoma who developed SCLE after nivolumab treatment, ultimately requiring systemic corticosteroids for management before entering hospice care due to metastatic disease.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!